• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

    5/8/25 10:20:37 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Viatris Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    92556V106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92556V106


    1Names of Reporting Persons

    DAVIS SELECTED ADVISERS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    COLORADO
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    62,570,471.00
    6Shared Voting Power

    7Sole Dispositive Power

    64,948,236.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    64,948,236.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Viatris Inc
    (b)Address of issuer's principal executive offices:

    1000 MYLAN BOULEVARD, 1000 MYLAN BOULEVARD, CANONSBURG, PENNSYLVANIA, 15317.
    Item 2. 
    (a)Name of person filing:

    Davis Selected Advisers
    (b)Address or principal business office or, if none, residence:

    2949 East Elvira Road, Suite 101 Tucson, Arizona 85756
    (c)Citizenship:

    See Item 4 of Cover Page
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    92556V106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    64,948,236 shares
    (b)Percent of class:

    6.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    62,570,471 shares

     (ii) Shared power to vote or to direct the vote:


     (iii) Sole power to dispose or to direct the disposition of:

    64,948,236 shares

     (iv) Shared power to dispose or to direct the disposition of:


    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DAVIS SELECTED ADVISERS
     
    Signature:/s/ Michaela McLoughry
    Name/Title:Vice President, Chief Compliance Officer
    Date:05/08/2025
    Get the next $VTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    4/24/2023$11.00Overweight → Equal Weight
    Barclays
    2/17/2023$16.00 → $14.00Outperform → Market Perform
    BMO Capital Markets
    1/27/2023$13.00 → $15.00Hold → Buy
    Jefferies
    11/10/2022$9.00 → $12.00Sell → Neutral
    UBS
    11/8/2022$10.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

      Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base BusinessMakes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive Commentary "2025 is off to a good start as we continue to focus on executing our strategic priorities," said Scott A. Smith, CEO, Viatris. "Our growing pipeline, capital discipline, operational execution, and

      5/8/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

      Treatment With XULANE LO Low Estrogen Dose Achieved Primary and All Secondary Efficacy and Safety Endpoints Results Demonstrated Potential Best-In-Class Patch Performance  New Drug Application Submission to U.S. FDA Anticipated in the Second Half of 2025 PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to

      5/8/25 6:45:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

      All Primary and Secondary Endpoints Were Met in Both Phase 3 Studies In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain Control Versus the Opioid Arm Targeting New Drug Application Submission to U.S. FDA by End of 2025 PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind,

      5/8/25 6:30:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

      SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)

      5/8/25 10:20:37 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Viatris Inc.

      10-Q - Viatris Inc (0001792044) (Filer)

      5/8/25 9:21:14 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Viatris Inc (0001792044) (Filer)

      5/8/25 7:53:40 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      10/25/24 4:30:03 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

      PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venu

      4/14/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

      PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit

      6/3/24 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Appoints Corinne Le Goff as Chief Commercial Officer

      PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology

      4/15/24 8:00:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Le Goff Corinne converted options into 41,112 shares and covered exercise/tax liability with 19,878 shares, increasing direct ownership by 101% to 42,331 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      4/16/25 6:00:03 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lyons Dillon Joellen

      4 - Viatris Inc (0001792044) (Issuer)

      3/10/25 6:00:08 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Campbell Paul

      4 - Viatris Inc (0001792044) (Issuer)

      3/10/25 6:00:07 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viatris Inc.

      SC 13G/A - Viatris Inc (0001792044) (Subject)

      11/12/24 1:41:20 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

      SC 13G/A - Viatris Inc (0001792044) (Subject)

      2/13/24 5:17:31 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Viatris Inc.

      SC 13G - Viatris Inc (0001792044) (Subject)

      2/9/24 1:10:51 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on Viatris with a new price target

      Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00

      7/19/24 8:34:32 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris downgraded by BofA Securities with a new price target

      BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously

      10/23/23 7:20:20 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris downgraded by Barclays with a new price target

      Barclays downgraded Viatris from Equal Weight to Underweight and set a new price target of $11.00

      6/23/23 7:26:38 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Financials

    Live finance-specific insights

    See more
    • Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

      Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base BusinessMakes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive Commentary "2025 is off to a good start as we continue to focus on executing our strategic priorities," said Scott A. Smith, CEO, Viatris. "Our growing pipeline, capital discipline, operational execution, and

      5/8/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Quarterly Dividend

      PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.  About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare nee

      5/7/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

      PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc

      3/28/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care